Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 7:02 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 121 - 140 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Positive Opinion on Orphan Designation from European Medicines Agency for OMS721; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Phase 3 Trial Protocol Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Phase 3 Patient Enrollment to Begin in Early February for OMS721 in IgAN
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Pediatric Approval Secured; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
3Q17 Financial Results Reported; OMIDRIA Blows Away Estimates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Outlook for 2018: OMIDRIA Sales Growth and OMS721Clinical Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
An Underrated Biopharma with a GPCR Engine; Initiating at Buy with $30 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
Q2 OMIDRIA and Outlook: I Tried It and I Liked It
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Breakthrough Designation for IgAN Reduces Regulatory Hurdles.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 5
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of May 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials: OMIDRIA In-Line, Cash Runway Potentially Covers 2017 Catalysts but Dependent on OMIDRIA Sales; Reiterate OUTPERFORM and $47 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L